Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use

Elizabeth A. Holly, Rosemary D Cress, David K. Ahn

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Oral contraceptive use and reproductive factors were investigated in a population-based case-control study of 452 women aged 25-59 years who were diagnosed with cutaneous malignant melanoma during the period 1981-1986 and 930 controls. Ever use of oral contraceptives was reported by 72 percent of melanoma patients and 79 percent of control subjects in this San Francisco Bay Area study, although duration of use was slightly longer for women with superficial spreading melanoma (5.5 years) than for controls (4.3 years). While some subgroups had elevated or reduced odds ratios, no consistent association was observed between cutaneous melanoma risk and oral contraceptive use when use was examined by duration, latency, age at dlagnosis, age at first use, and time period of first use. Neither number of live births nor age at birth of the first child was associated with risk for cutaneous melanoma; nor was a history of miscarriage, induced abortion, or endometrosis. No association was observed with regularity of menstrual periods or with use of fertility drugs or hormones to regulate menstrual periods. Women who reported expenencing hyperpigmeritation of facial skin during a prior pregnancy had a lowered risk for alt cutaneous melanoma (odds ratio (OR) = 0.64, 95% confidence interval (Cl) 0.44-0.93) and superficial spreading melanoma (OR = 0.54, 95% Cl 0.36-0.83). This effect was more pronounced for light-complexioned women (for superficial spreading melanoma, OR = 0.37, 95% Cl 0.20-0.70) than for women with a dark or medium complexion (for superficial spreading melanoma, OR = 0.84, 95% Cl 0.48-1.5). Women who reported use of acne medication also had a reduced risk of superficial spreading melanoma (OR = 0.55, 95% Cl 0.35-0.84). These results indicate an overall lack of effect of oral contraceptives on cutaneous melanoma risk in this population of women. The reduced melanoma nsks associated with hyperpigmentation during a prior pregnancy and use of acne medication (or related hormonal indications for its use) should be studied further. Am J Epidemiol 1995;141:943-50.

Original languageEnglish (US)
Pages (from-to)943-950
Number of pages8
JournalAmerican Journal of Epidemiology
Volume141
Issue number10
StatePublished - May 15 1995

Fingerprint

Oral Contraceptives
Melanoma
Skin
Odds Ratio
Acne Vulgaris
Fertility Agents
Pregnancy
Hyperpigmentation
Birth Order
San Francisco
Induced Abortion
Live Birth
Spontaneous Abortion
Population
Case-Control Studies
Hormones
Confidence Intervals
Light

Keywords

  • Contraceptives, oral
  • Melanoma
  • Risk factors
  • Women

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Epidemiology

Cite this

Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use. / Holly, Elizabeth A.; Cress, Rosemary D; Ahn, David K.

In: American Journal of Epidemiology, Vol. 141, No. 10, 15.05.1995, p. 943-950.

Research output: Contribution to journalArticle

@article{92ab07b8c1844806b69bf6decc365087,
title = "Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use",
abstract = "Oral contraceptive use and reproductive factors were investigated in a population-based case-control study of 452 women aged 25-59 years who were diagnosed with cutaneous malignant melanoma during the period 1981-1986 and 930 controls. Ever use of oral contraceptives was reported by 72 percent of melanoma patients and 79 percent of control subjects in this San Francisco Bay Area study, although duration of use was slightly longer for women with superficial spreading melanoma (5.5 years) than for controls (4.3 years). While some subgroups had elevated or reduced odds ratios, no consistent association was observed between cutaneous melanoma risk and oral contraceptive use when use was examined by duration, latency, age at dlagnosis, age at first use, and time period of first use. Neither number of live births nor age at birth of the first child was associated with risk for cutaneous melanoma; nor was a history of miscarriage, induced abortion, or endometrosis. No association was observed with regularity of menstrual periods or with use of fertility drugs or hormones to regulate menstrual periods. Women who reported expenencing hyperpigmeritation of facial skin during a prior pregnancy had a lowered risk for alt cutaneous melanoma (odds ratio (OR) = 0.64, 95{\%} confidence interval (Cl) 0.44-0.93) and superficial spreading melanoma (OR = 0.54, 95{\%} Cl 0.36-0.83). This effect was more pronounced for light-complexioned women (for superficial spreading melanoma, OR = 0.37, 95{\%} Cl 0.20-0.70) than for women with a dark or medium complexion (for superficial spreading melanoma, OR = 0.84, 95{\%} Cl 0.48-1.5). Women who reported use of acne medication also had a reduced risk of superficial spreading melanoma (OR = 0.55, 95{\%} Cl 0.35-0.84). These results indicate an overall lack of effect of oral contraceptives on cutaneous melanoma risk in this population of women. The reduced melanoma nsks associated with hyperpigmentation during a prior pregnancy and use of acne medication (or related hormonal indications for its use) should be studied further. Am J Epidemiol 1995;141:943-50.",
keywords = "Contraceptives, oral, Melanoma, Risk factors, Women",
author = "Holly, {Elizabeth A.} and Cress, {Rosemary D} and Ahn, {David K.}",
year = "1995",
month = "5",
day = "15",
language = "English (US)",
volume = "141",
pages = "943--950",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use

AU - Holly, Elizabeth A.

AU - Cress, Rosemary D

AU - Ahn, David K.

PY - 1995/5/15

Y1 - 1995/5/15

N2 - Oral contraceptive use and reproductive factors were investigated in a population-based case-control study of 452 women aged 25-59 years who were diagnosed with cutaneous malignant melanoma during the period 1981-1986 and 930 controls. Ever use of oral contraceptives was reported by 72 percent of melanoma patients and 79 percent of control subjects in this San Francisco Bay Area study, although duration of use was slightly longer for women with superficial spreading melanoma (5.5 years) than for controls (4.3 years). While some subgroups had elevated or reduced odds ratios, no consistent association was observed between cutaneous melanoma risk and oral contraceptive use when use was examined by duration, latency, age at dlagnosis, age at first use, and time period of first use. Neither number of live births nor age at birth of the first child was associated with risk for cutaneous melanoma; nor was a history of miscarriage, induced abortion, or endometrosis. No association was observed with regularity of menstrual periods or with use of fertility drugs or hormones to regulate menstrual periods. Women who reported expenencing hyperpigmeritation of facial skin during a prior pregnancy had a lowered risk for alt cutaneous melanoma (odds ratio (OR) = 0.64, 95% confidence interval (Cl) 0.44-0.93) and superficial spreading melanoma (OR = 0.54, 95% Cl 0.36-0.83). This effect was more pronounced for light-complexioned women (for superficial spreading melanoma, OR = 0.37, 95% Cl 0.20-0.70) than for women with a dark or medium complexion (for superficial spreading melanoma, OR = 0.84, 95% Cl 0.48-1.5). Women who reported use of acne medication also had a reduced risk of superficial spreading melanoma (OR = 0.55, 95% Cl 0.35-0.84). These results indicate an overall lack of effect of oral contraceptives on cutaneous melanoma risk in this population of women. The reduced melanoma nsks associated with hyperpigmentation during a prior pregnancy and use of acne medication (or related hormonal indications for its use) should be studied further. Am J Epidemiol 1995;141:943-50.

AB - Oral contraceptive use and reproductive factors were investigated in a population-based case-control study of 452 women aged 25-59 years who were diagnosed with cutaneous malignant melanoma during the period 1981-1986 and 930 controls. Ever use of oral contraceptives was reported by 72 percent of melanoma patients and 79 percent of control subjects in this San Francisco Bay Area study, although duration of use was slightly longer for women with superficial spreading melanoma (5.5 years) than for controls (4.3 years). While some subgroups had elevated or reduced odds ratios, no consistent association was observed between cutaneous melanoma risk and oral contraceptive use when use was examined by duration, latency, age at dlagnosis, age at first use, and time period of first use. Neither number of live births nor age at birth of the first child was associated with risk for cutaneous melanoma; nor was a history of miscarriage, induced abortion, or endometrosis. No association was observed with regularity of menstrual periods or with use of fertility drugs or hormones to regulate menstrual periods. Women who reported expenencing hyperpigmeritation of facial skin during a prior pregnancy had a lowered risk for alt cutaneous melanoma (odds ratio (OR) = 0.64, 95% confidence interval (Cl) 0.44-0.93) and superficial spreading melanoma (OR = 0.54, 95% Cl 0.36-0.83). This effect was more pronounced for light-complexioned women (for superficial spreading melanoma, OR = 0.37, 95% Cl 0.20-0.70) than for women with a dark or medium complexion (for superficial spreading melanoma, OR = 0.84, 95% Cl 0.48-1.5). Women who reported use of acne medication also had a reduced risk of superficial spreading melanoma (OR = 0.55, 95% Cl 0.35-0.84). These results indicate an overall lack of effect of oral contraceptives on cutaneous melanoma risk in this population of women. The reduced melanoma nsks associated with hyperpigmentation during a prior pregnancy and use of acne medication (or related hormonal indications for its use) should be studied further. Am J Epidemiol 1995;141:943-50.

KW - Contraceptives, oral

KW - Melanoma

KW - Risk factors

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=0029033432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029033432&partnerID=8YFLogxK

M3 - Article

C2 - 7741124

AN - SCOPUS:0029033432

VL - 141

SP - 943

EP - 950

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 10

ER -